Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan vs Atenolol on Exercise Capacity in Hypertensive Postmenopausal Women
NCT00171132Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2004
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of valsartan in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in exercise capacity measured by oxygen consumption during exercise testing at 26 weeks. Started Aug 2004; status: completed.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00171132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171132.